Abbott Laboratories
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total net sales (FY2025) | $44.33 billion, up 5.7% year-over-year reported / 5.5% organic |
| Net earnings, GAAP (FY2025) | $6.52 billion (diluted EPS $3.72) |
| Adjusted net earnings, non-GAAP (FY2025) | $9.04 billion (adjusted diluted EPS $5.15, up about 10% year-over-year) |
| Medical Devices organic sales growth (FY2025) | +11.9% (U.S. +13.4%, international +10.5%), led by Diabetes Care/FreeStyle Libre and structural heart |
| Diagnostics organic sales growth (FY2025) | -4.5% reported (-0.4% excluding COVID-19 testing), as pandemic-era testing demand continued to recede |
| FreeStyle Libre / CGM sales (FY2025) | Exceeded $7.5 billion, up 17% year-over-year - the third straight year CGM sales grew by more than $1 billion |
| Established Pharmaceuticals organic sales growth (FY2025) | +7.4% (entirely ex-U.S.; Abbott does not sell branded generics in the U.S.) |
| Employees worldwide (as of Dec 31, 2025) | Approximately 115,000, up roughly 1,000 from FY2024 (company-reported, 10-K) |
| U.S. CGM market share (calendar 2024, third-party estimate) | GlobalData estimated Dexcom held about 74% of the U.S. CGM market in 2024, with Abbott's FreeStyle Libre and Medtronic splitting most of the remaining ~26%; Abbott does not disclose its own CGM market share |
Sources: Revenue, segment net sales, net income and EPS figures are company-disclosed, from Abbott's Q4/FY2025 earnings release (reported January 22, 2026, filed as an 8-K exhibit with the SEC) and its FY2025 Form 10-K. Segment operating earnings (Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Medical Devices) are Abbott's disclosed segment figures from the 10-K's business segment note; all four segments were profitable in FY2025, so no loss-making segment was excluded. The four disclosed segments' net sales sum to about $44.31 billion, roughly $17 million (0.04%) below the $44.33 billion total net sales Abbott reports, a rounding gap inherent to Abbott's own disclosure. The CGM competitive-landscape figure is a third-party market-research estimate (GlobalData, as reported by Medical Device Network/Yahoo Finance) for the U.S. market only, not an Abbott-reported figure, and is presented as such.